Umezawa T, Kiba T, Numata K, Saito T, Nakaoka M, Shintani S, Sekihara H
Third Department of Internal Medicine, Yokohama City University, School of Medicine 3-9, Fukuura Kanazawa-ku, Yokohama 236-0004, Japan.
Anticancer Res. 2000 Nov-Dec;20(6B):4235-42.
Irinotecan (CPT-11) has been used recently for the treatment of several cancers in combination with 5-fluorouracil (5-FU). Preliminary data on this combination therapy in humans demonstrated no drug interactions between CPT-11 (or its metabolite, SN-38) and 5-FU however, because there is so little information on the combination, the possibility for an interaction still exists.
CPT-11 and 5-FU were injected intravenously into rats and the pharmacokinetics of CPT-11 and SN-38 and alternations in blood cell count were investigated.
In the group of rats administered 5-FU prior to CPT-11, the area under the concentration-time curve (AUC) of CPT-11 was approximately eight-fold larger compared with the group administered CPT-11 prior to 5-FU. On the other hand, the grade of leukocytopenia or thrombocytopenia was not significantly different among the two groups.
In rats, the conversion of CPT-11 into SN-38 is possibly delayed by prior administration of 5-FU.
伊立替康(CPT-11)近来已与5-氟尿嘧啶(5-FU)联合用于多种癌症的治疗。关于这种联合疗法在人体中的初步数据表明,CPT-11(或其代谢产物SN-38)与5-FU之间不存在药物相互作用,然而,由于关于这种联合用药的信息非常少,相互作用的可能性仍然存在。
将CPT-11和5-FU静脉注射到大鼠体内,研究CPT-11和SN-38的药代动力学以及血细胞计数的变化。
在CPT-11给药前先给予5-FU的大鼠组中,CPT-11的浓度-时间曲线下面积(AUC)比在5-FU给药前先给予CPT-11的组大约大8倍。另一方面,两组之间白细胞减少或血小板减少的程度没有显著差异。
在大鼠中,先给予5-FU可能会延迟CPT-11向SN-38的转化。